Navigation Links
Certain Drug Treatment Associated With Orofacial Clefts

A new study has confirmed the orofacial cleft (OFC) inducing effect of phenytoin, carbamazepine, oxytetracycline, and thiethylperazine//. A possible association was also suggested between OFCs and oxprenolol and amoxicillin. The study is published in the latest issue of Cleft Palate–Craniofacial Journal.

The study’s participants had been registered with the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. The study reviewed 1,374 cases of isolated cleft lip with or without cleft palate (CL/P), 601 cases with posterior cleft plate (PCP), 38,151 cases without birth defects used as the population controls, and 20,868 malformed controls with other defects.

Data was colleted from medical records, particularly prenatal logbooks, retrospective maternal data via a self-reported questionnaire, and home visits to non-responding mothers.

An increased risk for isolated CL/P was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and thiethylperazine during the second and third month of pregnancy, which is the critical period for isolated CL/P. The risk of isolated PCP was increased in mothers treated with oxytetracycline and carbamazepine during the third and fourth month of pregnancy, the critical period for developing PCP.

Source-Newswise
SR
'"/>




Page: 1

Related medicine news :

1. Almonds As Effective As Certain Drugs In Lowering Cholesterol
2. Certain Food Beneficial for the Heart
3. Sunlight Could Be Beneficial For Certain Types Of Cancer
4. Calcium Supplements May Not Be Useful After A Certain Threshold Is Achieved
5. Small Doses Of Radiation Can Help Certain Lung Cancer Patients
6. Effects Of Certain Food Related To Single Pain Receptors
7. Spices Could Be Employed To Treat Certain Cancers
8. Certain antidepressant drugs associated with pronounced suicidal tendencies
9. Elements In Grape fruit Juice Combine Lethally with Certain Drugs, leading to potentially dangerous side effects, study.
10. John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases
11. Hearing May be affected by Certain Hormone Replacement Therapies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: